Sharon Stone-Elander´s research group
Cognitive neurophysiology - medical radiochemistry
Our research focuses on developing methods for detecting and visualizing disease processes. Through the use of molecular imaging techniques, we characterize and measure biological processes in vivo. We link basic research with the clinic by implementing common imaging platforms (primarily positron emission tomography (PET)) in studies ranging from experimental models to humans, with an ultimate gain of improving the ways that health care decisions are made.
Our areas of expertise include developing new radiotracers, performing pharmacokinetic evaluations in vivo, using novel and conventional PET biomarkers in disease models without and with therapeutic interventions and performing in vitro and in vivo evaluations of their utilization and metabolism, with the possibility of coupling the most promising findings to clinical research and clinical trials.
- PET imaging methods for monitoring disease progression and therapeutic response
Vascular endothelial growth factor B controls endothelial fatty acid uptake.
Nature 2010 Apr;464(7290):917-21
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.
Eur. J. Nucl. Med. Mol. Imaging 2009 Aug;36(8):1283-95
On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
J. Nucl. Med. 2009 Mar;50(3):417-25